Bionet

Bionet Current Liabilities

The Current Liabilities of Bionet (1784.TWO) as of Nov 2, 2026 is 80.77 M TWD. In the previous year, Current Liabilities was 199.12 M TWD — a change of -59.44% (lower).

Current Liabilities

80.77 MTWD

YoY

-59.44%

Last updated:

Current Liabilities of Bionet is 2025 80.77 M TWD. Current Liabilities of Bionet was 2024 199.12 M TWD. It decreases by -59.44% lower compared to the previous year.

The Bionet Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
127.91 M TWD
Jan 1, 2019
143.62 M TWD
Jan 1, 2020
65.21 M TWD
Jan 1, 2021
68.29 M TWD
Jan 1, 2022
75.28 M TWD
Jan 1, 2023
231.61 M TWD
Jan 1, 2024
199.12 M TWD
Jan 1, 2025
80.77 M TWD
The Bionet Current Liabilities history
YEARCurrent LiabilitiesYoY
80.77 MTWD-59.44%
199.12 MTWD-14.03%
231.61 MTWD+207.67%
75.28 MTWD+10.24%
68.29 MTWD+4.71%
65.21 MTWD-54.59%
143.62 MTWD+12.28%
127.91 MTWD+8.04%
118.40 MTWD-34.29%
180.18 MTWD+0.98%
178.42 MTWD+20.68%
147.84 MTWD-9.20%
162.82 MTWD-13.27%
187.73 MTWD+1.10%
185.68 MTWD+11.36%
166.73 MTWD+7.13%
155.64 MTWD+27.11%
122.44 MTWD+24.98%
97.96 MTWD+52.13%
64.39 MTWD+15.25%
55.87 MTWD+16.30%
48.04 MTWD-21.22%
60.98 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

Current Liabilities of Bionet is 80.77 M TWD in 2025.

Current Liabilities of Bionet changed from 199.12 M TWD to 80.77 M TWD, representing a -59.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Bionet since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Bionet historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bionet

All Key Metrics — Bionet